TSG6は,TSG6-CD44-TGFβR1またはEGFR複合体の形成を促進することによって,Smad2/3およびMAPKシグナル伝達を通じて,上皮質-メセンキマの移行および腫瘍関連マクロファージの極化を促進する.
PubMedで要約を見る
まとめ
この要約は機械生成です。腫瘍死滅因子アルファ刺激遺伝子/タンパク質6 (TSG6) は,上皮-メゼンキマ移行 (EMT) を強化し,免疫細胞を再プログラムすることによって,肺がんの進行を促進します. TSG6をターゲットにすることで,肺腺がん (LUAD) の治療戦略が提供される可能性があります.
科学分野
- 腫瘍学
- 免疫学
- 分子生物学
背景
- 肺腺がん (LUAD) の腫瘍微環境 (TME) の TSG6 の役割は不明である.
- TSG6は,PLK1誘発の上皮質-メゼンキマ移行 (EMT) 時に高濃度で発現する.
- TSG6とPLK1の高い共発は,LUAD患者における生存率の低下と相関する.
研究 の 目的
- LUAD TME内の免疫可塑性におけるTSG6の機能と規制メカニズムを調査する.
- EMTにおけるTSG6の役割とCD44との関連を明らかにする.
- TSG6がM2d腫瘍関連マクロファージ (TAM) への単細胞の偏化にどのように影響するかを決定する.
主な方法
- TSG6とPLK1の発現を LUAD患者データで分析した.
- 肺がん細胞系 (A549,HCC827) をTSG6で治療し,EMTマーカーを観察する.
- THP-1単細胞と共同培養システムを用いて,TAMの分極化を研究する.
- TSG6結合パートナーを特定するために免疫降水を使用します.
- TSG6によって活性化される信号経路 (TGFβR1,EGFR,MAPK/ERK) を調査する.
主要な成果
- TSG6とCD44は,TGF-βまたはPLK1-駆動EMTで上位調節されます.
- TSG6治療はEMTを強化し,N-カデリンとp-Smad2を増加させます.
- TSG6は,M2d TAMにTHP-1単細胞の偏化を引き起こす.
- TSG6はCD44と結合し,TGFβR1またはEGFRとの相互作用を促進する.
- TSG6はTGFβR1/SmadとMAPK/ERK経路を活性化し,CD44レベルとその分裂ドメインを増加させます.
結論
- TSG6は,LUADにおけるEMTとM2d-TAMの極化を促進する.
- TSG6はCD44と相互作用し,TGFβR1/SmadとMAPK/ERKのシグナリングを活性化することで効果を発揮する.
- TSG6は,がん細胞の可塑性と免疫微環境の両方に影響を及ぼすことによって,LUADの潜在的な治療標的を表しています.
関連する概念動画
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

